Pages that link to "Q28256092"

The following pages link to The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial (Q28256092):

Displayed 50 items.

• Does HAART efficacy translate to effectiveness? Evidence for a trial effect (Q21135313) ‎ (← links)
• Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy (Q24234853) ‎ (← links)
• Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials* (Q27015850) ‎ (← links)
• HIV protease inhibitors: a review of molecular selectivity and toxicity (Q28082749) ‎ (← links)
• Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen (Q28477151) ‎ (← links)
• Challenges in initiating antiretroviral therapy in 2010. (Q30227046) ‎ (← links)
• Noninfectious Diarrhea in HIV Seropositive Individuals: a Review of Prevalence Rates, Etiology, and Management in the Era of Combination Antiretroviral Therapy (Q30609066) ‎ (← links)
• Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data (Q30652267) ‎ (← links)
• Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study (Q33578024) ‎ (← links)
• Abacavir/lamivudine combination in the treatment of HIV: a review. (Q33715435) ‎ (← links)
• The inclusion of historical control data may reduce the power of a confirmatory study (Q33854238) ‎ (← links)
• Antiretroviral therapy in the clinic (Q33877347) ‎ (← links)
• Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data (Q33891656) ‎ (← links)
• Antiretroviral medication adherence and class- specific resistance in a large prospective clinical trial (Q33917546) ‎ (← links)
• 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis (Q34134900) ‎ (← links)
• Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis (Q34251223) ‎ (← links)
• Antiretroviral therapies in women after single-dose nevirapine exposure (Q34363980) ‎ (← links)
• Current perspectives in HIV post-exposure prophylaxis (Q34434815) ‎ (← links)
• Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study (Q34481365) ‎ (← links)
• Protease Inhibitors for Patients With HIV-1 Infection: A Comparative Overview (Q34631149) ‎ (← links)
• Adherence-resistance relationships to combination HIV antiretroviral therapy (Q34634212) ‎ (← links)
• Deficient reporting and interpretation of non-inferiority randomized clinical trials in HIV patients: a systematic review. (Q34713094) ‎ (← links)
• Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems (Q34730407) ‎ (← links)
• HIV protease inhibitors and obesity (Q34792983) ‎ (← links)
• Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials (Q35109199) ‎ (← links)
• Antiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committee (Q35124959) ‎ (← links)
• Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa (Q35179391) ‎ (← links)
• Management of HIV infection in treatment-naive patients: a review of the most current recommendations (Q35188723) ‎ (← links)
• Lack of protease inhibitor resistance following treatment failure--too good to be true? (Q35237578) ‎ (← links)
• Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens (Q35792853) ‎ (← links)
• Spillover adherence effects of fixed-dose combination HIV therapy (Q35808707) ‎ (← links)
• Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients (Q35963960) ‎ (← links)
• Dyslipidemias and Elevated Cardiovascular Risk on Lopinavir-Based Antiretroviral Therapy in Cambodia (Q36118338) ‎ (← links)
• High prevalence of PI resistance in patients failing second-line ART in Vietnam (Q36551309) ‎ (← links)
• Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients (Q36567732) ‎ (← links)
• British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). (Q36653838) ‎ (← links)
• Abacavir/lamividune combination in the treatment of HIV-1 infection: a review (Q36675417) ‎ (← links)
• Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections (Q36723780) ‎ (← links)
• Fosamprenavir calcium plus ritonavir for HIV infection (Q36839698) ‎ (← links)
• Antiretroviral treatment of HIV infection: Swedish recommendations 2007. (Q36852859) ‎ (← links)
• HIV-1 drug resistance mutations: an updated framework for the second decade of HAART (Q36900010) ‎ (← links)
• Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules (Q36926668) ‎ (← links)
• Translating efficacy into effectiveness in antiretroviral therapy: beyond the pill count (Q36947022) ‎ (← links)
• Considering metabolic issues when initiating HIV therapy (Q36947452) ‎ (← links)
• Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials (Q36993465) ‎ (← links)
• Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification (Q37003795) ‎ (← links)
• Antiretroviral therapy : optimal sequencing of therapy to avoid resistance (Q37032556) ‎ (← links)
• Current clinical treatments of AIDS. (Q37034589) ‎ (← links)
• Development of protease inhibitors and the fight with drug-resistant HIV-1 variants (Q37034610) ‎ (← links)
• Crofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDS (Q37042269) ‎ (← links)